Neurocrine Biosciences, Inc. (NASDAQ:NBIX) had its target price hoisted by stock analysts at BMO Capital Markets to $109.00 in a report issued on Thursday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 75.50% from the stock’s current price.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and issued a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Robert W. Baird restated an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Finally, Needham & Company LLC restated a “buy” rating and issued a $58.00 target price on shares of Neurocrine Biosciences in a research note on Sunday, September 17th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $73.06.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the previous year, the business earned ($0.43) earnings per share.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/neurocrine-biosciences-inc-nbix-price-target-raised-to-109-00.html.

In other news, insider Haig P. Bozigian sold 22,500 shares of Neurocrine Biosciences stock in a transaction on Friday, August 4th. The shares were sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the completion of the sale, the insider now directly owns 154,601 shares in the company, valued at $7,730,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the sale, the insider now owns 101,790 shares of the company’s stock, valued at $5,852,925. The disclosure for this sale can be found here. Insiders have sold 123,846 shares of company stock valued at $7,004,150 over the last quarter. Insiders own 4.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Trust Advisors LP lifted its position in Neurocrine Biosciences by 29.0% during the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after purchasing an additional 176,136 shares during the period. Canada Pension Plan Investment Board lifted its position in Neurocrine Biosciences by 49.7% during the second quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock valued at $1,136,000 after purchasing an additional 8,200 shares during the period. BlackRock Inc. lifted its position in Neurocrine Biosciences by 14,216.0% during the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after purchasing an additional 4,996,784 shares during the period. Point72 Asset Management L.P. acquired a new position in Neurocrine Biosciences during the first quarter valued at $4,330,000. Finally, Schwab Charles Investment Management Inc. lifted its position in Neurocrine Biosciences by 8.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 346,906 shares of the company’s stock valued at $15,022,000 after purchasing an additional 27,245 shares during the period.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

The Fly

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.